HRTS ETF

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.

The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. An interview with the PM increased my understanding and confidence in the portfolio construction and strategy.

Losing weight has always been difficult for many individuals, myself included. It is estimated that around 1 billion people are currently living with obesity, with projections suggesting this number could increase to 1.9 billion by 2035 according to the Obesity World Atlas.